197 related articles for article (PubMed ID: 27315783)
1. Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child-Pugh B cirrhosis.
Terashima T; Yamashita T; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Mizukoshi E; Honda M; Kaneko S
Cancer Sci; 2016 Sep; 107(9):1263-9. PubMed ID: 27315783
[TBL] [Abstract][Full Text] [Related]
2. Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients.
Moriya K; Namisaki T; Sato S; Furukawa M; Douhara A; Kawaratani H; Kaji K; Shimozato N; Sawada Y; Saikawa S; Takaya H; Kitagawa K; Akahane T; Mitoro A; Yamao J; Yoshiji H
Clin Mol Hepatol; 2019 Dec; 25(4):381-389. PubMed ID: 31405269
[TBL] [Abstract][Full Text] [Related]
3. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
[TBL] [Abstract][Full Text] [Related]
4. A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy.
Saeki I; Yamasaki T; Tanabe N; Iwamoto T; Matsumoto T; Urata Y; Hidaka I; Ishikawa T; Takami T; Yamamoto N; Uchida K; Terai S; Sakaida I
PLoS One; 2015; 10(5):e0126649. PubMed ID: 25992784
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus.
Nagai H; Mukozu T; Ogino YU; Matsui D; Matsui T; Wakui N; Momiyama K; Igarashi Y; Sumino Y; Higai K
Anticancer Res; 2015 Apr; 35(4):2269-77. PubMed ID: 25862889
[TBL] [Abstract][Full Text] [Related]
6. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A.
Lee BH; Lee DS; Cho CW; Yun SS
World J Surg Oncol; 2019 Aug; 17(1):143. PubMed ID: 31416447
[TBL] [Abstract][Full Text] [Related]
7. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
Ando E; Tanaka M; Yamashita F; Kuromatsu R; Yutani S; Fukumori K; Sumie S; Yano Y; Okuda K; Sata M
Cancer; 2002 Aug; 95(3):588-95. PubMed ID: 12209752
[TBL] [Abstract][Full Text] [Related]
8. Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
Kanekawa T; Nagai H; Kanayama M; Sumino Y
Cancer Chemother Pharmacol; 2014 Nov; 74(5):899-909. PubMed ID: 25138286
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant hepatic chemotherapy after resection of solitary hepatocellular carcinoma associated with hepatitis B virus cirrhosis.
Wen J; Shen WL; Yang SH
Hepatobiliary Pancreat Dis Int; 2006 May; 5(2):224-7. PubMed ID: 16698580
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma.
Baek YH; Kim KT; Lee SW; Jeong JS; Park BH; Nam KJ; Cho JH; Kim YH; Roh YH; Lee HS; Choi YM; Han SY
World J Gastroenterol; 2012 Jul; 18(26):3426-34. PubMed ID: 22807613
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy.
Oh MJ; Lee HJ; Lee SH
Clin Mol Hepatol; 2013 Sep; 19(3):288-99. PubMed ID: 24133667
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
Yamasaki T; Kimura T; Kurokawa F; Aoyama K; Ishikawa T; Tajima K; Yokoyama Y; Takami T; Omori K; Kawaguchi K; Tsuchiya M; Terai S; Sakaida I; Okita K
J Gastroenterol; 2005 Jan; 40(1):70-8. PubMed ID: 15692792
[TBL] [Abstract][Full Text] [Related]
13. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB
Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870
[TBL] [Abstract][Full Text] [Related]
14. [Hepatic Arterial Infusion Chemotherapy Using a Reservoir for Advanced Hepatocellular Carcinoma].
Sato T; Takahashi Y; Imai M; Isokawa O
Gan To Kagaku Ryoho; 2016 Jan; 43(1):73-7. PubMed ID: 26809529
[TBL] [Abstract][Full Text] [Related]
15. [Successful Hepatic Arterial Injection Chemotherapy for Hepatocellular Carcinoma with Inferior Vena Cava Invasion and Extrahepatic Spread in a Patient with Child-Pugh Class BLiver Cirrhosis].
Kajiyama Y; Kikuchi K; Obi S; Miyakawa H; Sato S; Yasuda I
Gan To Kagaku Ryoho; 2018 Sep; 45(9):1339-1341. PubMed ID: 30237377
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Outcome of Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma by the Combination of RECIST and Tumor Markers.
Hatooka M; Kawaoka T; Aikata H; Honda F; Nakamura Y; Nakano N; Morio K; Fukuhara T; Kobayashi T; Nagaoki Y; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Awai K; Chayama K
Hiroshima J Med Sci; 2016 Sep; 65(2):25-33. PubMed ID: 29989682
[TBL] [Abstract][Full Text] [Related]
17. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy.
Niizeki T; Sumie S; Torimura T; Kurogi J; Kuromatsu R; Iwamoto H; Aino H; Nakano M; Kawaguchi A; Kakuma T; Sata M
J Gastroenterol; 2012 Jun; 47(6):686-95. PubMed ID: 22382631
[TBL] [Abstract][Full Text] [Related]
18. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
Lai YC; Shih CY; Jeng CM; Yang SS; Hu JT; Sung YC; Liu HT; Hou SM; Wu CH; Chen TK
World J Gastroenterol; 2003 Dec; 9(12):2666-70. PubMed ID: 14669309
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinoma.
Xiao Y; Deng W; Luo L; Zhu G; Xie J; Liu Y; Wan R; Wen W; Hu Z; Shan R
BMC Cancer; 2024 May; 24(1):588. PubMed ID: 38745113
[TBL] [Abstract][Full Text] [Related]
20. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
